Description
MDV-3100 (Enzalutamide) is an androgen-receptor (AR) antagonist (IC₅₀ = 36 nM). Prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex. MDV 3100 has also been shown to induce tumor cell apoptosis, and has no agonist activity. MDV 3100 is a candidate for the treatment of castration-resistant prostate cancer.
MDV-3100 (Enzalutamide) is an androgen-receptor (AR) antagonist (IC₅₀ = 36 nM). Prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex. MDV 3100 has also been shown to induce tumor cell apoptosis, and has no agonist activity. MDV 3100 is a candidate for the treatment of castration-resistant prostate cancer.
Alternate Name/Synonyms: 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide; Enzalutamide
Appearance: White solid
Formulation: N/A
CAS Number: 915087-33-1
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: N/A
Molecular Formula: C₂₁H₁₆F₄N₄O₂S
Molecular Weight: 464.43
Cell-Permeable?: Yes
Purity: ≥98% by HPLC
Solubilities: DMSO (~25 mg/ml)
Handling: Protect from air and light
Country of Origin: USA
Tag Line: An androgen-receptor (AR) antagonist
MDL Number: N/A
PubChem CID: 15951529
SMILES: CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C
InChi: InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)
InChi Key: WXCXUHSOUPDCQV-UHFFFAOYSA-N
Additional Information
Storage Condition: |
-20°C |
Shipping Condition: |
Gel Pack |
Shelf Life: |
36 months |